Tenaya Therapeutics Stock Shares Owned By Institutions
| TNYA Stock | USD 0.73 0.02 2.82% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Tenaya Therapeutics' long-term financial health and intrinsic value.
Tenaya | Shares Owned By Institutions | Build AI portfolio with Tenaya Stock |
Tenaya Therapeutics Company Shares Owned By Institutions Analysis
Tenaya Therapeutics' Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Tenaya Therapeutics Shares Owned By Institutions | 41.47 % |
Most of Tenaya Therapeutics' fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tenaya Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tenaya Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Tenaya Therapeutics is extremely important. It helps to project a fair market value of Tenaya Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Tenaya Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tenaya Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tenaya Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 41.47% of Tenaya Therapeutics are shares owned by institutions. This is 7.1% lower than that of the Biotechnology sector and 12.69% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 5.76% lower than that of the firm.
Tenaya Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tenaya Therapeutics' direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tenaya Therapeutics could also be used in its relative valuation, which is a method of valuing Tenaya Therapeutics by comparing valuation metrics of similar companies.Tenaya Therapeutics is currently under evaluation in shares owned by institutions category among its peers.
Tenaya Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Tenaya Therapeutics from analyzing Tenaya Therapeutics' financial statements. These drivers represent accounts that assess Tenaya Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Tenaya Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 631.3M | 782.5M | 90.1M | 239.1M | 274.9M | 475.3M | |
| Enterprise Value | 502.7M | 758.0M | 9.9M | 205.8M | 236.7M | 411.4M |
Tenaya Fundamentals
| Return On Equity | -0.96 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | 109.26 M | ||||
| Shares Outstanding | 216.51 M | ||||
| Shares Owned By Insiders | 0.45 % | ||||
| Shares Owned By Institutions | 41.47 % | ||||
| Number Of Shares Shorted | 22.19 M | ||||
| Price To Book | 1.86 X | ||||
| EBITDA | (102.66 M) | ||||
| Net Income | (111.13 M) | ||||
| Cash And Equivalents | 180.92 M | ||||
| Cash Per Share | 4.37 X | ||||
| Total Debt | 13.61 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.91 X | ||||
| Book Value Per Share | 0.51 X | ||||
| Cash Flow From Operations | (90.5 M) | ||||
| Short Ratio | 3.79 X | ||||
| Earnings Per Share | (0.75) X | ||||
| Target Price | 9.43 | ||||
| Number Of Employees | 97 | ||||
| Beta | 3.14 | ||||
| Market Capitalization | 159.07 M | ||||
| Total Asset | 119.94 M | ||||
| Retained Earnings | (514.41 M) | ||||
| Working Capital | 51.4 M | ||||
| Net Asset | 119.94 M |
About Tenaya Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tenaya Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tenaya Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tenaya Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Check out Tenaya Therapeutics Piotroski F Score and Tenaya Therapeutics Altman Z Score analysis. For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenaya Therapeutics. If investors know Tenaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenaya Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Tenaya Therapeutics is measured differently than its book value, which is the value of Tenaya that is recorded on the company's balance sheet. Investors also form their own opinion of Tenaya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenaya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenaya Therapeutics' market value can be influenced by many factors that don't directly affect Tenaya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tenaya Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenaya Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenaya Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.